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Abstract
Background: In 1997 Vagus Nerve Stimulation (VNS) received approval from the US Food and Drug Administration
(FDA) as an adjunctive therapy in the treatment of medically intractable partial epilepsy in people aged 12 years
and older who are ineligible for resective epilepsy surgery. Although the exact mechanisms of action are unknown,
the use of VNS with children has increased, including those younger than 12 years of age, or those with
generalized epilepsy.
Methods: We describe the outcome for the first group of nine patients, aged 8-28 years, who had pharmaco-
resistant epilepsy and were treated with VNS. During the follow up, we gradually and slowly increased the
parameters of the stimulation in order to assess the efficacy of VNS even at parameters which would usually be
considered “non-therapeutic”, along with possible side effects and changes in quality of life.
Results: At the last follow, up 1 patient was “seizures free”, 3 were “very good responders”, 3 were “good
responders” and 2 were “non responders”. We obtained an initial seizure reduction with low stimulation
parameters, the highest current reached being 2.00 mA. This observation supports the possibility that, for younger
patients, lower stimulation intensities than those commonly used in clinical practice for adults can be therapeutic.
We also wanted to underline the reduction in seizure frequency (~91,7%) and the reduction in seizure duration
(> 50%) in the patients affected by drug-resistant absence epilepsy. Adverse effects were mild, tolerable and, in
most of cases, easily resolved by adjusting the stimulation parameters. Hoarseness of voice was the most frequent
side effect. The improvements in the quality of life are relevant and seem to be independent of the VNS effect in
controlling seizures.
Conclusions: Our small experience seems to confirm the efficacy and safety of VNS in drug resistant partial and
generalized epilepsy in developing age groups.
Background
In 1997 Vagus Nerve Stimulation (VNS) received
approval from the US Food and Drug Administration
(FDA) as an adjunctive therapy in the treatment of
medically intractable partial epilepsy in people aged 12
years and older [1,2] who are ineligible for resective epi-
lepsy surgery [3,4]. Although the exact mechanisms of
action are unknown, the use of VNS in children has
increased, including in those aged under 12 and in those
with generalized epilepsy. It is evident that VNS offers
substantial therapeutic benefits to some patients, with-
out causing major side effects [3]. VNS is not usually
associated with the common central nervous system
side effects, such as dizziness, ataxia, insomnia, cognitive
impairment, or weight gain [5], which sometimes limit
the use of AEDs.
We describe the outcome for the first group of
patients with pharmaco-resistant epilepsy who were
treated with VNS at the Child Neuropsychiatric Unit of
S.Orsola-Malpighi Hospital, University of Bologna
(Italy).
Materials and methods
Our study included nine patients, five females and four
males, aged 8-28 years with pharmaco-resistant epilepsy
(Table 1). Patient 1 presents absence epilepsy, patient 2
and 3 present partial epilepsy secondary to herpetic
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epilepsy due to a double cortex, patient 5 and 7 present
partial epilepsy probably symptomatic, patient 6 and 8
present symptomatic partial epilepsy due to peri-natal
sufferance, patient 9 is affected by Lennox-Gastaut
syndrome.
They had received from 7 to 15 different anti-epileptic
drugs and were not eligible for surgical resection. VNS
was implanted in the period June 2007- June 2009. The
follow-up lasted 5 to 29 months. After VNS implanta-
tion, patients had clinical examinations every 15-30 days
in which we evaluated the frequency, intensity and dura-
tion of their seizures, the side effects, and any changes
in their quality of life, on the basis of a diary filled in by
the family, without the support of any standardized
questionnaires. During the follow up, we regulated the
stimulation parameters, which were gradually and slowly
increased, in order to assess the efficacy of VNS at para-
meters which would usually be considered “non-thera-
peutic” [3]. The efficacy of the treatment was measured
as the percentage change in seizures at each visit. The
stimulation parameters were adjusted in line with
standard medical practice for VNS implanted patients
[5]. Initial stimulation parameters were: output current =
0.25 mA, frequency = 30 Hz, pulse width = 500 μs, sig-
nal on-time = 30 sec and off-time = 180 minutes. The
stimulus intensity was increased stepwise by 0.25 mA
up to a maximum of 2.00. In addition, the off-time was
reduced from 180 minutes to 5 minutes. We did not
change the frequency or the duration of the stimulus,
other than in two cases in which there was the onset of
side effects (hoarseness). As regards Quality of Life
(QOL), we considered improvements in alertness, verbal
communication, memory, school/professional achieve-
ment, mood, and reduction in post-ictal state and in sei-
zure clustering [5]. No changes to drugs were made,
other than for two patients who experienced a worsen-
ing in their clinical patterns.
Results
No initial surgical complications were reported in this
cohort of patients and no complications caused by
implantation were reported. All children were known to
have the devices in place and functioning.
Table 1 Our patients
Etiology Age Duration
of
epilepsy
Seizure Type VNS stimulation
parameters associated
with seizures reduction
Syndrome Follow-
up
Actual VNS
stimulation
parameters
Seizures
frequency
1
Idiopathic
16 y 9 y Generalised seizures I: 1.75 mA;
T off: 5 min
Absence epilepsy 29 m I: 1.75 mA;
T off: 5 min
Very good
responder
> 75%
2
Symptomatic
8 y 7 y Drop attacks, partial
seizures with
secondary
generalization
i: 2.00 mA;
T off: 5 min
Partial epilepsy
secondary to herpetic
encephalitis
29 m i: 2.00 mA;
T off: 5 min
Good
responder
> 50%
3
Symptomatic
11 y 10 y Drop attacks, partial
seizures
i: 1.25 mA;
T off: 5 min
Partial epilepsy
secondary to herpetic
encephalitis
26 m i: 1.50 mA;
T off: 5 min
Very good
responder
>75%
4
Symptomatic
26 y 17 y Partial ? Partial epilepsy
due to double cortex
22 m i: 1.50 mA;
F: 20 Hz
T off: 5 min
Non
responder
5
Probably
Symptomatic
11 y 11 y Partial i: 1.50 mA;
T off: 40 min
Probably symptomatic
epilepsy
22 m i: 1.50 mA;
T off: 5 min
Good
responder
> 50%
6
Symptomatic
28 y 28 y Partial seizures with
secondary
generalization
I: 1.25 mA;
T off: 180 min
Symptomatic partial
epilepsy due to peri-
natal sufferance
13 m i: 2.00 mA;
T off: 25 min
Non
responder
7
Probably
Symptomatic
23 y 4 y Partial seizures with
secondary
generalization
i: 0.50 mA;
T off: 180 min
Probably symptomatic
epilepsy
10 m i: 1.00 mA;
T off: 45 min
Seizures
free
8
Symptomatic
17 y 11 y Partial seizures with
secondary
generalization
i: 1.25 mA;
T off: 120 min
Symptomatic partial
epilepsy due to peri-
natal sufferance
8 m i: 1.25 mA;
T off: 90 min
Very good
responder
>75%
9
Probably
Symptomatic
14 y 14 y Partial seizures with
secondary
generalization
i: 1.25 mA;
T off: 120 min
Lennox-Gastaut
syndrome
6 m i: 1.25 mA;
T off: 90 min
Very good
responder
>75%
Initial VNS stimulation parameters: i: 0.25 mA, F: 30 Hz, A: 500 μs, T on: 30 s, T off: 180 min
m: months
y: years
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Page 2 of 6Only 3 months from implantation, drop attacks had
disappeared in one patient and decreased in another.
From the third month of treatment, patient 1 (table 1)
with drug-resistant absence epilepsy experienced a reduc-
tion in the intensity and duration of absences, and this
positive result remained constant. After nine months of
treatment, the patient showed a 91,7% reduction in sei-
zure frequency and a reduction in seizure duration of
more than 50% (from 20-40 s down to 6-20 s). These
data were confirmed at follow-up over 29 months.
At the last follow up, 1 patient was “seizure free” with
a follow-up duration of 10 months, 4 were “very good
responders” because of a reduction in fits of more than
75%, 2 of these with a follow-up duration more than 12
months. 2 patients were “good responders” with a sei-
zure reduction of more than 50%, both with a follow-up
duration more than 12 months; 2 patients were “non-
responders” after a follow-up duration more than 12
months.
Magnet activation was used by the patients or by care-
givers in case of frequent seizures. One patient reported
that the magnet was effective in aborting or decreasing
the intensity or duration of her seizures. Two patients
reported that the magnet had no effect, while two
patients had not yet used the magnet.
The improvement in the quality of life was particularly
relevant for 7 patients, and this seemed to be indepen-
dent of the VNS effect in controlling seizures. No speci-
fic test was used.
In general, the best results were achieved in alertness
(7 patients), verbal communication (5 patients) and in
reduction in post-ictal state (6 patients) (Figure 1).
From the third month of treatment, 2/9 patients
showed an increase in alertness, verbal communication
and reduction in post-ictal state, 2/9 in alertness and
reduction in post-ictal state, 1/9 in alertness, verbal
communication, mood and reduction in post-ictal state,
1/9 in alertness, verbal communication, mood, reduction
in post-ictal state and school achievement, and 1/9 in
alertness, verbal communication, memory, mood and
school achievement. In contrast, 2/9 showed no increase
in QOL, one of whom continued to complain of severe
weariness, this probably being caused by a recently diag-
nosed and as yet untreated hypothyroidism.
In our patients these improvements in QOL were
reported by parents even if they did not referred a
reduction of seizures. This suggests that the improve-
ments in QOL may be independent of the anti-seizure
effect that VNS has.
Discussion
The longest follow-up in this series was 29 months;
therefore, the results are still preliminary.
Our small experience with VNS seems to confirm the
efficacy of the treatment in the reduction of the fre-
quency and intensity of seizures in drug-resistant epi-
lepsy at developing age. Multiple studies have shown a
slightly higher response rate in children as compared
with adults, and the longer-term follow-ups (> 5 years)
in children have shown a 50% decrease in seizure fre-
quency in about 60% of patients, with a 75% decrease in
40% of patients, though overall numbers are still low [6].
In accordance with other experiences [7,8], we
observed an initial decrease in daily seizure frequency
and the occurrence of seizure-free days. As time went
by, more seizure-free days and fewer seizure days were
achieved, with decreased severity and reduction in post-
ictal state. Sometimes seizure-free periods coalesced into
Figure 1 Improvement in Quality of Life (QOL) in our patients.
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Page 3 of 6weeks, with seizure days becoming more and more dis-
tant from each other. On the same grounds there
seemed to be a reasonable reduction in the utilization of
healthcare services, with less accesses in the emergency
room, and the time spent on epilepsy-related tasks [6].
The low number of patients did not allow us to evaluate
the type of seizure which is most responsive to VNS ther-
apy, though it should be noted that after only 3 months of
therapy, drop attacks stopped in one patient and were
reduced in one, this observation confirming the notable
efficacy of VNS therapy in controlling drop attacks [3,4,7].
We would underline the fact that patient 1 (table 1)
presenting with absence drug-resistant epilepsy showed
a reduction in seizure frequency of 91,7% and a reduc-
tion in seizure duration of more than 50% after 9
months of treatment. Before the implantation seizures
duration was from 20 to 40 s in every EEGs, whereas
after VNS implantation it was lower, however never
l o n g e rt h a n2 0s( F i g u r e2 ,3 ) .T h i sd a t u mw a sc o n -
firmed after 29 months of follow-up. Until now, there
have been few reports showing the effects of VNS in
patients with absences [9-11], which are not considered
the main indication for VNS treatment. This patient
satisfied diagnostic criteriaf o rC h i l d h o o dA b s e n c eE p i -
lepsy (CAE), characterized by the occurrence of frequent
absences in otherwise normal children. The age of onset
is around 6-8 years and the ictal EEG classically shows
paroxysms of generalized bilateral synchronous 3 Hz
spike-waves on a normal background activity [12]. Exact
descriptions of the course and prognosis of childhood
epilepsies, including CAE, have been inconsistent in ear-
lier studies, probably because of methodological differ-
ences and variations in patient inclusion criteria [12].
Most studies classified the absence epilepsy according to
the criteria of the ILAE of 1989 [13] or the criteria as
defined by Loiseau in 1992 [14]. It was observed that a
patient fulfilling the stricter criteria of ILAE had signifi-
cantly higher remission rates, fewer GTCS, and shorter
mean treatment periods. These strict criteria have been
accepted by the ILAE Task Force for Classification and
Terminology in 2005 [15] and in a study of 2007 was
confirmed that children fulfilling them, have a signifi-
cantly better outcome [16].
Earlier age at onset, the appearance of generalized
tonic-clonic seizures (GTCSs), difficult and incomplete
response to treatment, and the absence of seizure with
focal onset of abnormalities, were considered to be fac-
tors indicating an unfavorable prognosis [12,17,18]. The
pharmaco-resistance was confirmed in this patient by
the fact that various drugs (more than 5) were used.
EEG activity and the clinical features of our patient sug-
gested an unfavorable prognosis. We observed long dis-
charges at 3 Hz with frontal onset (Figure 2). These
data associated with a long duration of epilepsy suggest
that a natural improvement in the course of epilepsy is
not frequent, in particular in this kind of patient.
Another goal of our observation was to attempt to
evaluate the efficacy of VNS with lower stimulation
parameters.
The level of the stimulation parameters is still contro-
versial and there are no guide-lines, only some indica-
tions, these being not to exceed a stimulation current of
2,00 mA and to keep a standard cycle of 5 min OFF
and 3 min ON. We obtained an initial reduction in sei-
zures using low stimulation parameters (stimulation cur-
rent of 1,25 mA; ON 30 sec, OFF 120 min) in patients
n°8 and n°9, who were very good responders (Table 1).
The patient who was seizures-free obtained an initial
reduction in seizures with the following parameters: sti-
mulation current of 0,50 mA; ON 30 sec, OFF 180 min.
At the time of writing, the stimulation current being
used was 1.00 mA.
Figure 2 EEG of a patient before VNS implantation.
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Page 4 of 6Patient n°4 was a non responder: we did not report the
initial VNS stimulation parameters because we did not see
any improvement in the frequency of seizures, although
we reached a higher stimulation current (Table 1).
This observation suggests the possibility that lower sti-
mulation intensities can be therapeutic, not only for
children but also in young patients.
A d v e r s ee f f e c t sw e r em i l d ,t o l e r a b l ea n d ,i nm o s to f
cases, easily resolved by adjusting stimulation para-
meters in our patients. These side effects appear parti-
cularly mild and infrequent, above all, if compared with
the undesirable effects caused by the anti-epileptic drugs
taken by the patients. The most frequent side effect was
hoarseness of voice during the ON periods of stimula-
tion. This discomfort was persistent in one patient,
whereas in four others hoarseness of voice was reduced
by modifying the pulse width. In another patient, we
noticed a partial escape from the pocket of bipolar lead
in the chest, though device functioning was not compro-
mised. The child developed a hypertrophic chest scar. In
three cases, no VNS-related side effects were reported.
VNS side effects can also include weight loss [19]. The
regulation of feeding behavior is complex and poorly
understood, and the effect of VNS therapy on body
weight is unclear: VNS can cause weight loss by
engaging vagal afferents from the gastrointestinal tract
which mediates satiety [19].A n i m a le x p e r i m e n t sh a v e
shown that stimulation of the vagus nerve effectively
reduces eating, with a corresponding weight loss [20].
These type of studies have not been performed in
humans and it may be necessary to design a vagal
pacing therapy that mimics vagal activity in fasting or
fed states. Koren and Holmes [19] studied weight
changes in patients who were receiving VNS for the
treatment of medically refractory epilepsy: no significant
weight changes were noted during the two years after
VNS implantation and no relationship was found
between changes in seizure frequency and the effect on
body weight. In our study no patients suffered from this
side effect.
There was also an improvement in QOL for all
patients, except in two cases. These improvements
involved each aspect of QOL considered (alertness, ver-
bal communication, memory, school/professional
achievement, mood, post-ictal state, seizure clustering)
and were independent from the efficacy of VNS [6,21].
In addition, further observations of QOL were suggested
by the decreased seizure severity, the fact that seizures
were mostly nocturnal with fewer or no drop attacks,
the reduction in the utilization of healthcare services,
Figure 3 EEG of a patient after VNS implantation.
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Page 5 of 6and the time spent on epilepsy-related tasks. In conclu-
sion, despite the small group of patients studied, our
experience lends a small but clear support to confirming
the efficacy and safety of VNS in drug resistant partial
and generalized epilepsy at developing age, but we need
a larger group of patients to report more details on the
response of individual seizure types.
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